MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa1304923

Медицинская библиотека · The New England journal of medicine · 2014

Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China.

Zhu Fengcai, Xu Wenbo, Xia Jielai, Liang Zhenglun, Liu Yan, Zhang Xuefeng, Tan Xiaojuan, Wang Ling, Mao Qunying, Wu Junyu, Hu Yuemei, Ji Tianjiao, Song Lifei, Liang Qi, Zhang Baomin, Gao Qiang, Li Jingxin, Wang Shenyu, Hu Yuansheng, Gu Shanru, Zhang Jianhua, Yao Genhong, Gu Jianxiang, Wang Xushan, Zhou Yuchun, Chen Changbiao, Zhang Minglei, Cao Minquan, Wang Junzhi, Wang Hua, Wang Nan

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Enterovirus 71 (EV71) is one of the major causative agents of outbreaks of hand, foot, and mouth disease or herpangina worldwide. This phase 3 trial was designed to evaluate the efficacy, safety, and immunogenicity of an EV71 vaccine.

METHODS

We conducted a randomized, double-blind, placebo-controlled, multicenter trial in which 10,007 healthy infants and young children (6 to 35 months of age) were randomly assigned in a 1:1 ratio to receive two intramuscular doses of either EV71 vaccine or placebo, 28 days apart. The surveillance period was 12 months. The primary end point was the occurrence of EV71-associated hand, foot, and mouth disease or herpangina.

RESULTS

During the 12-month surveillance period, EV71-associated disease was identified in 0.3% of vaccine recipients (13 of 5041 children) and 2.1% of placebo recipients (106 of 5028 children) in the intention-to-treat cohort. The vaccine efficacy against EV71-associated hand, foot, and mouth disease or herpangina was 94.8% (95% confidence interval [CI], 87.2 to 97.9; P<0.001) in this cohort. Vaccine efficacies against EV71-associated hospitalization (0 cases vs. 24 cases) and hand, foot, and mouth disease with neurologic complications (0 cases vs. 8 cases) were both 100% (95% CI, 83.7 to 100 and 42.6 to 100, respectively). Serious adverse events occurred in 111 of 5044 children in the vaccine group (2.2%) and 131 of 5033 children in the placebo group (2.6%). In the immunogenicity subgroup (1291 children), an anti-EV71 immune response was elicited by the two-dose vaccine series in 98.8% of participants at day 56. An anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71-associated hand, foot, and mouth disease or herpangina.

CONCLUSIONS

The EV71 vaccine provided protection against EV71-associated hand, foot, and mouth disease or herpangina in infants and young children. (Funded by Sinovac Biotech; ClinicalTrials.gov number, NCT01507857.).

Для цитирования: Zhu Fengcai, Xu Wenbo, Xia Jielai, Liang Zhenglun, Liu Yan, Zhang Xuefeng, Tan Xiaojuan, Wang Ling, Mao Qunying, Wu Junyu, Hu Yuemei, Ji Tianjiao, Song Lifei, Liang Qi, Zhang Baomin, Gao Qiang, Li Jingxin, Wang Shenyu, Hu Yuansheng, Gu Shanru, Zhang Jianhua, Yao Genhong, Gu Jianxiang, Wang Xushan, Zhou Yuchun, Chen Changbiao, Zhang Minglei, Cao Minquan, Wang Junzhi, Wang Hua, Wang Nan. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China.. The New England journal of medicine. 2014. DOI: 10.1056/nejmoa1304923.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.